Opinion

Video

Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos